Gene therapies that restore dystrophin expression for the treatment of Duchenne muscular dystrophy

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Human Genetics

• Publication date

  2016-08-20

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00439-016-1725-zPMID 27542949PMCID PMC5006996
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Title Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas 9

  2018cited by this paper
• Eteplirsen in the treatment of Duchenne muscular dystrophy

  2017cited by this paper
• A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells.

  2016cited by this paper
• Engineering Delivery Vehicles for Genome Editing.

  2016cited by this paper
• Rationally engineered Cas 9 nucleases with improved specificity Citation

  2016cited by this paper
• In vivo gene editing in dystrophic mouse muscle and muscle stem cells

  2016cited by this paper
• 731. High-Fidelity CRISPR-Cas9 Nucleases with No Detectable Genome-Wide Off-Target Effects

  2016cited by this paper
• CRISPR-mediated Genome Editing Restores Dystrophin Expression and Function in mdx Mice.

  2016cited by this paper
• Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy

  2016cited by this paper
• Engineering AAV receptor footprints for gene therapy.

  2016cited by this paper
• In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy

  2016cited by this paper
• Genome-wide target specificities of CRISPR-Cas9 nucleases revealed by multiplex Digenome-seq

  2016cited by this paper
• Genome Engineering Using Adeno-associated Virus: Basic and Clinical Research Applications.

  2016cited by this paper
• Efficient Restoration of the Dystrophin Gene Reading Frame and Protein Structure in DMD Myoblasts Using the CinDel Method

  2016cited by this paper
• Genome-editing Technologies for Gene and Cell Therapy

  2016influential reference
• The science to look out for in 2016

  2015cited by this paper
• Current Understanding of Molecular Pathology and Treatment of Cardiomyopathy in Duchenne Muscular Dystrophy

  2015cited by this paper
• The Pathogenesis and Therapy of Muscular Dystrophies.

  2015cited by this paper
• Rationally engineered Cas9 nucleases with improved specificity

  2015cited by this paper
• Viral vector-mediated gene therapies.

  2015cited by this paper
• Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers

  2015cited by this paper
• Creating and evaluating accurate CRISPR-Cas9 scalpels for genomic surgery

  2015cited by this paper
• Therapeutic genome editing: prospects and challenges

  2015cited by this paper
• An update on RNA-targeting therapies for neuromuscular disorders.

  2015influential reference
• Correction: Long Term Natural History Data in Ambulant Boys with Duchenne Muscular Dystrophy: 36-Month Changes

  2015cited by this paper
• Duchenne Muscular Dystrophy: From Diagnosis to Therapy

  2015cited by this paper
• Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy

  2015cited by this paper
• An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies.

  2015cited by this paper
• Coaxing stem cells for skeletal muscle repair.

  2015cited by this paper
• Cardiomyopathy in Duchenne Muscular Dystrophy: Current Value of Clinical, Electrophysiological and Imaging Findings in Children and Teenagers

  2015cited by this paper
• Gene therapy for Duchenne muscular dystrophy

  2015cited by this paper
• Gene therapy returns to centre stage

  2015cited by this paper
• High-fidelity CRISPR-Cas9 variants with undetectable genome-wide off-targets

  2015cited by this paper
• Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells

  2015cited by this paper
• Multiplex CRISPR/Cas9-Based Genome Editing for Correction of Dystrophin Mutations that Cause Duchenne Muscular Dystrophy

  2015cited by this paper
• Exon skipping therapy for Duchenne muscular dystrophy.

  2015cited by this paper
• Full-Length Dystrophin Reconstitution with Adeno-Associated Viral Vectors

  2014cited by this paper
• Precise Correction of the Dystrophin Gene in Duchenne Muscular Dystrophy Patient Induced Pluripotent Stem Cells by TALEN and CRISPR-Cas9

  2014cited by this paper
• Development and applications of CRISPR-Cas9 for genome engineering.

  2014influential reference
• New developments in exon skipping and splice modulation therapies for neuromuscular diseases

  2014cited by this paper
• Correction of Dystrophin Expression in Cells From Duchenne Muscular Dystrophy Patients Through Genomic Excision of Exon 51 by Zinc Finger Nucleases

  2014cited by this paper
• Molecular Diagnosis of Duchenne Muscular Dystrophy

  2014cited by this paper
• Triple Trans-Splicing Adeno-Associated Virus Vectors Capable of Transferring the Coding Sequence for Full-Length Dystrophin Protein into Dystrophic Mice

  2014cited by this paper
• Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study.

  2014influential reference
• Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice

  2014cited by this paper
• Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA

  2014cited by this paper
• Forelimb treatment in a large cohort of dystrophic dogs supports delivery of a recombinant AAV for exon skipping in Duchenne patients.

  2014cited by this paper
• Prevention of muscular dystrophy in mice by CRISPR/Cas9–mediated editing of germline DNA

  2014cited by this paper
• Long Term Natural History Data in Ambulant Boys with Duchenne Muscular Dystrophy: 36-Month Changes

  2014cited by this paper
• Translational and Regulatory Challenges for Exon Skipping Therapies

  2014cited by this paper
• Synthetic Zinc Finger Proteins: The Advent of Targeted Gene Regulation and Genome Modification Technologies

  2014cited by this paper
• GUIDE-Seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases

  2014cited by this paper
• Microdystrophin ameliorates muscular dystrophy in the canine model of duchenne muscular dystrophy.

  2013cited by this paper
• Six-Minute Walk Test: Reference Values and Prediction Equation in Healthy Boys Aged 5 to12 Years

  2013cited by this paper
• Reading Frame Correction by Targeted Genome Editing Restores Dystrophin Expression in Cells From Duchenne Muscular Dystrophy Patients

  2013cited by this paper
• Eteplirsen for the treatment of Duchenne muscular dystrophy

  2013cited by this paper
• ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering.

  2013influential reference
• An ex vivo Gene Therapy Approach to Treat Muscular Dystrophy Using inducible Pluripotent Stem Cells

  2013cited by this paper
• Antisense Therapy in Neurology

  2013cited by this paper
• Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids.

  2013cited by this paper
• THE 6-MINUTE WALK TEST AND OTHER ENDPOINTS IN DUCHENNE MUSCULAR DYSTROPHY: LONGITUDINAL NATURAL HISTORY OBSERVATIONS OVER 48 WEEKS FROM A MULTICENTER STUDY

  2013cited by this paper
• Erratum: Reading Frame correction by targeted genome editing restores dystrophin expression in cells from duchenne muscular dystrophy patients (Molecular Therapy (2013) 21 (1718-1726) DOI: 10.1038/mt.2013.111)

  2013cited by this paper
• Gene Correction of a Duchenne Muscular Dystrophy Mutation by Meganuclease-Enhanced Exon Knock-In

  2013cited by this paper
• AAV micro-dystrophin gene therapy alleviates stress-induced cardiac death but not myocardial fibrosis in >21-m-old mdx mice, an end-stage model of Duchenne muscular dystrophy cardiomyopathy.

  2012cited by this paper
• Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping.

  2012cited by this paper
• TALENs: a widely applicable technology for targeted genome editing

  2012influential reference
• Exon-skipping therapy for Duchenne muscular dystrophy.

  2012influential reference
• Bodywide skipping of exons 45–55 in dystrophic mdx52 mice by systemic antisense delivery

  2012cited by this paper
• Novel insight into stem cell trafficking in dystrophic muscles

  2012cited by this paper
• Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping

  2012cited by this paper
• Long-term restoration of cardiac dystrophin expression in golden retriever muscular dystrophy following rAAV6-mediated exon skipping.

  2012cited by this paper
• Rescue of nonsense mutations by amlexanox in human cells

  2012cited by this paper
• Human ES- and iPS-derived myogenic progenitors restore DYSTROPHIN and improve contractility upon transplantation in dystrophic mice.

  2012cited by this paper
• Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy

  2012cited by this paper
• Repeat-Dose Toxicology Evaluation in Cynomolgus Monkeys of AVI-4658, a Phosphorodiamidate Morpholino Oligomer (PMO) Drug for the Treatment of Duchenne Muscular Dystrophy

  2011cited by this paper
• The I-CreI meganuclease and its engineered derivatives: applications from cell modification to gene therapy.

  2011influential reference
• In vivo genome editing restores hemostasis in a mouse model of hemophilia

  2011cited by this paper
• The status of exon skipping as a therapeutic approach to duchenne muscular dystrophy.

  2011cited by this paper
• Long‐term functional adeno‐associated virus‐microdystrophin expression in the dystrophic CXMDj dog

  2011cited by this paper
• AAV-microdystrophin therapy improves cardiac performance in aged female mdx mice.

  2011cited by this paper
• Design and testing of regulatory cassettes for optimal activity in skeletal and cardiac muscles.

  2011cited by this paper
• Codon optimization of the microdystrophin gene for Duchene muscular dystrophy gene therapy.

  2011cited by this paper
• In Situ Genetic Correction of the Sickle Cell Anemia Mutation in Human Induced Pluripotent Stem Cells Using Engineered Zinc Finger Nucleases

  2011cited by this paper
• A TALE nuclease architecture for efficient genome editing

  2011cited by this paper
• Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease.

  2011cited by this paper
• Chemical and Mechanistic Toxicology Evaluation of Exon Skipping Phosphorodiamidate Morpholino Oligomers in mdx Mice

  2011cited by this paper
• Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study

  2011cited by this paper
• Meganucleases and Other Tools for Targeted Genome Engineering: Perspectives and Challenges for Gene Therapy

  2011cited by this paper
• Systemic administration of PRO051 in Duchenne's muscular dystrophy.

  2011influential reference
• The 6‐minute walk test as a new outcome measure in Duchenne muscular dystrophy

  2010cited by this paper
• Diagnosis and management of Duchenne muscular dystrophy

  2010cited by this paper
• Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs.

  2010cited by this paper
• Preclinical PK and PD Studies on 2′-O-Methyl-phosphorothioate RNA Antisense Oligonucleotides in the mdx Mouse Model

  2010cited by this paper
• Safety Pharmacology and Genotoxicity Evaluation of AVI-4658

  2010cited by this paper
• Past, present and future of myoblast transplantation in the treatment of Duchenne muscular dystrophy

  2010cited by this paper
• Meganucleases can restore the reading frame of a mutated dystrophin

  2010cited by this paper
• Becker muscular dystrophy patients with deletions around exon 51; a promising outlook for exon skipping therapy in Duchenne patients.

  2010cited by this paper
• Dystrophin immunity in Duchenne's muscular dystrophy.

  2010cited by this paper
• Genome editing with engineered zinc finger nucleases

  2010cited by this paper
• Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort

  2009cited by this paper

• Pharmacological Treatments and Therapeutic Targets in Muscle Dystrophies Generated by Alterations in Dystrophin-Associated Proteins

  2024cites this paper
• Respiratory Characterization of a Humanized Duchenne Muscular Dystrophy Mouse Model.

  2024cites this paper
• Duchenne and Becker muscular dystrophy: Cellular mechanisms, image analysis, and computational models: A review

  2024cites this paper
• Multi-omics research in sarcopenia: Current progress and future prospects.

  2022cites this paper
• Injectable Hydrogel Microspheres for Sustained Gene Delivery of Antisense Oligonucleotides to Restore the Expression of Dystrophin Protein in Duchenne Muscular Dystrophy

  2022cites this paper
• Jumping Mechanography is a Suitable Complementary Method to Assess Motor Function in Ambulatory Boys with Duchenne Muscular Dystrophy

  2021cites this paper
• Duchennova mišična distrofija – novosti pri diagnosticiranju in zdravljenju

  2021cites this paper
• A new therapeutic effect of fenofibrate in Duchenne muscular dystrophy: The promotion of myostatin degradation

  2021cites this paper
• Case Report: Identification of Maternal Low-Level Mosaicism in the Dystrophin Gene by Droplet Digital Polymerase Chain Reaction

  2021cites this paper
• Genetik menschlicher Erkrankungen

  2020cites this paper
• Structural Perturbations of Exon Skipping Edits within the Dystrophin D20:24 Region

  2020cites this paper
• Microtubule Regulation of Mitochondrial Bioenergetics in Cardiac and Skeletal Muscles

  2020cites this paper
• - O -Methyl RNA/Ethylene-Bridged Nucleic Acid Chimera Antisense Oligonucleotides to Induce Dystrophin Exon 45 Skipping Antisense oligonucleotide

  2020cites this paper
• [Maintenance of Plasmid Expression in vivo Depends Primarily on the CpG Contents of the Vector and Transgene].

  2020cites this paper
• In Vivo Genome Engineering for the Treatment of Muscular Dystrophies

  2020cites this paper
• Maintenance of Plasmid Expression in vivo Depends Primarily on the CpG Contents of the Vector and Transgene

  2020cites this paper
• Is Exercise-Induced Fatigue a Problem in Children with Duchenne Muscular Dystrophy?

  2020cites this paper
• Heterogenetic parabiosis between healthy and dystrophic mice improve the histopathology in muscular dystrophy

  2020cites this paper
• Comparative proteomic analyses of Duchenne muscular dystrophy and Becker muscular dystrophy muscles: changes contributing to preserve muscle function in Becker muscular dystrophy patients

  2020cites this paper
• Expectations and anxieties of Duchenne muscular dystrophy patients and their families during the first-in-human clinical trial of NS-065/NCNP-01.

  2020cites this paper
• Coenzyme Q10 supplementation acts as antioxidant on dystrophic muscle cells

  2019cites this paper
• Muscle fibrosis in the soft palate: Delivery of cells, growth factors and anti-fibrotics.

  2019cites this paper
• More than a messenger: Alternative splicing as a therapeutic target.

  2019influential citation
• Cytoplasmic nucleic acid-based XNAs directly enhance live cardiac cell function by a Ca2+ cycling-independent mechanism via the sarcomere.

  2019cites this paper
• Qualification opinion on stride velocity 95th centile as a secondary endpoint in Duchenne Muscular Dystrophy measured by a valid and suitable wearable device

  2019cites this paper
• Genome Editing for Muscle Gene Therapy

  2019cites this paper
• Human induced pluripotent stem cell models for the study and treatment of Duchenne and Becker muscular dystrophies

  2019cites this paper
• Gene Therapy for Facioscapulohumeral Muscular Dystrophy (FSHD)

  2019cites this paper
• CRISPR/Cas9 gene-editing: Research technologies, clinical applications and ethical considerations.

  2018cites this paper
• A CRISPR Approach for a Common Inherited Disease: Researchers at Duke University Hope Gene Editing Can Eliminate Mutations That Lead to Duchenne Muscular Dystrophy

  2018cites this paper
• Determination of qPCR Reference Genes Suitable for Normalizing Gene Expression in a Canine Model of Duchenne Muscular Dystrophy

  2018cites this paper
• Duchenne muscular dystrophy: genome editing gives new hope for treatment

  2018cites this paper
• Flow Cytometry-Defined CD49d Expression in Circulating T-Lymphocytes Is a Biomarker for Disease Progression in Duchenne Muscular Dystrophy.

  2018cites this paper
• Diltiazem improves contractile properties of skeletal muscle in dysferlin‐deficient BLAJ mice, but does not reduce contraction‐induced muscle damage

  2018cites this paper
• Monitoring disease activity noninvasively in the mdx model of Duchenne muscular dystrophy

  2018cites this paper
• CRISPR Craft: DNA Editing the Reconstructive Ladder

  2018cites this paper
• A new era in the management of Duchenne muscular dystrophy

  2018cites this paper
• Long-term Evaluation of AAV-CRISPR Genome Editing for Duchenne Muscular Dystrophy

  2018cites this paper
• The potential of utrophin modulators for the treatment of Duchenne muscular dystrophy

  2018cites this paper
• Diagnostik und Therapie der Muskeldystrophien

  2018cites this paper
• Tratamiento farmacológico y génico en las distrofias musculares de Duchenne y Becker

  2018influential citation
• Placenta-derived mesenchymal stromal cells and their exosomes exert therapeutic effects in Duchenne muscular dystrophy.

  2018cites this paper
• Motor Development and Disorders

  2018cites this paper
• Duchenne and Becker Muscular Dystrophies: A Review of Animal Models, Clinical End Points, and Biomarker Quantification

  2017influential citation
• Pharmacological advances for treatment in Duchenne muscular dystrophy.

  2017cites this paper
• FDA-Approved Oligonucleotide Therapies in 2017.

  2017cites this paper
• Genomic integration of the full-length dystrophin coding sequence in Duchenne muscular dystrophy induced pluripotent stem cells.

  2017cites this paper
• Advances and challenges of using CRISPR-Cas9 gene editing for treating Duchenne muscular dystrophy

  2017cites this paper
• Does Sarcolipin Ablation Alter Deflazacort Treatment Effects in mdx Mice

  2017cites this paper
• Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: results of a two-year open-label extension trial

  2017cites this paper
• Emerging new tools to study and treat muscle pathologies: genetics and molecular mechanisms underlying skeletal muscle development, regeneration, and disease

  2017cites this paper
• Dystrophinopathies and Limb-Girdle Muscular Dystrophies

  2017cites this paper
• Pediatric Cardiomyopathies.

  2017cites this paper
• Genome engineering: a new approach to gene therapy for neuromuscular disorders

  2017cites this paper
• Structural insights on biologically relevant cationic membranes by ESR spectroscopy

  2017cites this paper
• 2′-O-Methyl RNA/Ethylene-Bridged Nucleic Acid Chimera Antisense Oligonucleotides to Induce Dystrophin Exon 45 Skipping

  2017cites this paper
• In vivo RNA targeting of point mutations via suppressor tRNAs and adenosine deaminases

  2017cites this paper
• The natural history of the patients with Duchenne muscular dystrophy in Taiwan: A medical center experience.

  2017cites this paper
• Clinical and mutational characteristics of Duchenne muscular dystrophy patients based on a comprehensive database in South China.

  2017cites this paper
• CRISPR/Cas9-mediated genome editing induces exon skipping by alternative splicing or exon deletion

  2017cites this paper
• tRNAs and adenosine deaminases

  2017cites this paper
• Modulation of aberrant splicing in human RNA diseases by chemical compounds

  2017cites this paper
• Eteplirsen Approved for Duchenne Muscular Dystrophy: The FDA Faces a Difficult Choice.

  2016cites this paper
• Increased Expression of Laminin Subunit Alpha 1 Chain by dCas9-VP160

  2016cites this paper
• Biomedical applications of gene editing

  2016cites this paper